Core Viewpoint - The acquisition of 20.31% stake in Guofu Quantum by Huajian Medical for approximately HKD 31.42 billion signifies a strategic move to enhance its business landscape and capitalize on the burgeoning RWA market [1][2]. Group 1: Strategic Considerations - The acquisition is driven by Huajian Medical's development needs and the trends in the RWA industry, which is projected to reach a market size of USD 16 trillion by 2030, accounting for 10% of global GDP [2]. - Huajian Medical aims to create a new growth curve through the establishment of the world's first innovative drug intellectual property RWA exchange, ivd.xyz, utilizing a "NewCo + RWA + stablecoin" model to tokenize high-value medical assets [2][3]. - The RWA technology allows for the segmentation of early-stage innovative drug pipeline assets into smaller tokens, broadening financing channels and improving efficiency [2]. Group 2: Market Opportunities - In the first half of 2025, China's innovative drug License-out total reached approximately USD 66 billion, surpassing the total BD transaction amount for 2024, indicating a significant opportunity for Huajian Medical's RWA business [3]. - Guofu Quantum, with its comprehensive financial licenses and expertise in quantum computing, AI, and blockchain, complements Huajian Medical's RWA strategy, addressing challenges such as the scarcity of financial licenses and expertise in digital assets [3][4]. Group 3: Business Synergy - The collaboration between Huajian Medical and Guofu Quantum is expected to create a complete ecosystem for the tokenization of innovative drug intellectual property, leveraging Huajian's medical industry resources and Guofu's financial technology capabilities [4]. - Huajian Medical can utilize Guofu Quantum's 22.5% stake in Southern Dongying to build a blockchain and financial technology-centric on-chain financial ecosystem, promoting asset tokenization and cross-border flow [4]. Group 4: Future Growth Potential - Post-acquisition, Huajian Medical is poised to expand its RWA asset types and enhance its market competitiveness by leveraging Guofu Quantum's resources [5][6]. - The partnership is expected to attract more enterprises into the RWA ecosystem, facilitating the tokenization of assets beyond innovative drugs and enhancing Huajian Medical's role as a bridge between Chinese assets and global capital [6][7]. - With the growing RWA market, Huajian Medical's unique position in the medical asset tokenization space, combined with its upgraded financial licenses and technical capabilities, positions it favorably for future competition [7]. Group 5: Conclusion - The acquisition represents a significant resource integration effort, aiming to reconstruct the link between finance and industry through RWA, with Huajian Medical potentially becoming a model for the digitalization of quality Chinese assets and compliant global capital allocation [8]. - The deepening synergy between the two companies may drive a new paradigm in the RWA industry, transitioning from single asset tokenization to a comprehensive ecosystem value co-creation [8].

智通财经APP获悉，2025年9月1日，华检医疗（01931）宣布以31.42亿港元收购国富量子（00290）20.31%股权，成为这家拥有香港1、4、6、9号金融 牌照的量子科技公司的控股股东。 这笔交易不仅是一次资本运作，更是华检医疗构建全球RWA代币化数字交易平台的关键一步。通过这次收购，华检医疗获得了国富量子在数字资产和 RWA领域的专业能力和金融牌照资源，为其RWA交易所生态系统注入强劲动力。 一、交易细节：一场价值31亿港元的收购 根据买卖协议，华检医疗全资附属公司以每股约9.69港元的价格配发及发行3.24亿股代价股份，收购国富量子20.31%股权。交易完成后，华检医疗将 持有国富量子20.31%的股份，成为其控股股东。 华检医疗9月1日公告 这次收购是两家公司在战略上的高度协同。 华检医疗原为医疗检测设备分销企业，自2025年7月起股价表现活跃，两个月内累计涨幅近480%，市值一度突破160亿港元。这一变化源于公司积极 推进区块链战略，构建全球首个创新药知识产权RWA交易所ivd.xyz。该平台采用"NewCo+RWA+稳定币"模式，致力于将高价值医疗资产（如ADC药 物、基因疗法专利等）代币 ...

Group 1 - The core point of the news is that Huajian Medical has acquired a 20.31% stake in Guofu Quantum for HKD 3.142 billion, becoming the controlling shareholder, which is a strategic move to build a global RWA tokenized digital trading platform [1][2][7] - The acquisition involves Huajian Medical's subsidiary issuing approximately 324 million shares at around HKD 9.69 per share to complete the purchase [2] - This acquisition is seen as a significant step for Huajian Medical, which has shifted from being a medical equipment distributor to actively pursuing blockchain strategies, including the establishment of the world's first RWA trading platform for innovative drug intellectual property [5][8] Group 2 - The strategic collaboration between Huajian Medical and Guofu Quantum is expected to create a complete ecosystem for the tokenization of medical innovation drug intellectual property and high-tech assets of publicly listed companies [8][9] - Guofu Quantum, holding multiple financial licenses, enhances Huajian Medical's capabilities in the digital asset and RWA sectors, while Huajian Medical provides financial support and resources from the medical industry [6][8] - The RWA trading platform developed by Huajian Medical aims to connect real-world assets with global capital, potentially positioning the company as a dominant player in the RWA sector, similar to Alibaba's role in connecting SMEs with global markets [9][10] Group 3 - The strategic initiatives align with national policies promoting the global market development of innovative drugs, supported by recent regulatory advancements in digital asset management in Hong Kong and the U.S. [10] - The RWA market is experiencing significant growth, with a total locked value (TVL) reaching USD 12.5 billion by mid-2025, indicating a strong upward trend in asset tokenization [12] - Despite the promising outlook, challenges such as liquidity issues and regulatory complexities remain critical factors for the RWA market's development [11]